Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + Radiotherapy in Esophageal Cancer
NCT02591784Phase 2Completed
- Start
- Nov 2008
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in esophageal cancer. Primary endpoint: Rate of Adverse Events or Toxicity at 3 months. Started Nov 2008; status: completed.
02
Drugs
nimotuzumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02591784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591784.